Sotac Pharmaceuticals

Sotac Pharmaceuticals EBITDA-margin

EBITDA-margin for Sotac Pharmaceuticals (SOTAC.NS) pr. 22. okt. 2026 er 14,07 %. I foregående år var EBITDA-margin 7,98 % — en ændring på 76,45 % (højere).

EBITDA-margin

14,07 %

YoY

76,45%

Senest opdateret:

EBITDA-margin for Sotac Pharmaceuticals er 2025 14,07 % . EBITDA-margin for Sotac Pharmaceuticals var 2024 7,98 % . Det falder dermed med 76,45% højere sammenlignet med året før.

Sotac Pharmaceuticals EBITDA-margin historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

EBITDA-margin
Dato
EBITDA-margin
1. jan. 2020
6,51 INR
1. jan. 2021
2,98 INR
1. jan. 2022
10,90 INR
1. jan. 2023
14,16 INR
1. jan. 2024
7,98 INR
1. jan. 2025
14,07 INR
Sotac Pharmaceuticals EBITDA-margin historik
ÅREBITDA-marginYoY
14,07 %+76,45%
7,98 %-43,66%
14,16 %+29,91%
10,90 %+265,87%
2,98 %-54,24%
6,51 %—

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Sotac Pharmaceuticals Aktieanalyse

Hvad laver Sotac Pharmaceuticals? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Sotac Pharmaceuticals aktie

EBITDA-margin for Sotac Pharmaceuticals er 14,07 % i 2025.

EBITDA-margin for Sotac Pharmaceuticals ændrede sig fra 7,98 % til 14,07 %, hvilket repræsenterer en ændring på 76,45 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af EBITDA-margin Sotac Pharmaceuticals siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

EBITDA-marginen viser, hvilken procentdel af omsætningen der konverteres til EBITDA. Den normaliserer for af- og nedskrivninger og kapitalstrukturforskelle.

En 'god' varierer efter branche og virksomhedens udviklingsstadium. På Eulerpool kan du sammenligne EBITDA-margins Sotac Pharmaceuticals med konkurrenter og branchegjennemsnittet for at afgøre, om den er attraktiv.

For at evaluere EBITDA-margins er det afgørende at sammenligne det med andre virksomheder i samme branche og sektor. På Eulerpool kan du finde branchsammenligninger for EBITDA-margin.

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Marginer — Sotac Pharmaceuticals

Alle nøgletal — Sotac Pharmaceuticals